File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

TitleCOVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease
Authors
KeywordsCOVID-19
2019-nCoV
Chinese Medicine
Integrative Medicine
Guideline
Issue Date2020
PublisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtml
Citation
The American Journal of Chinese Medicine, 2020, v. 48 n. 3, p. 737-762 How to Cite?
AbstractAs of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7–10% and median time to intensive care admission is 9.5–10.5 days with mortality of around 1–2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.
Persistent Identifierhttp://hdl.handle.net/10722/283261
ISSN
2019 Impact Factor: 3.682
2015 SCImago Journal Rankings: 0.797
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, KW-
dc.contributor.authorWong, VCW-
dc.contributor.authorTang, SCW-
dc.date.accessioned2020-06-22T02:54:16Z-
dc.date.available2020-06-22T02:54:16Z-
dc.date.issued2020-
dc.identifier.citationThe American Journal of Chinese Medicine, 2020, v. 48 n. 3, p. 737-762-
dc.identifier.issn0192-415X-
dc.identifier.urihttp://hdl.handle.net/10722/283261-
dc.description.abstractAs of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7–10% and median time to intensive care admission is 9.5–10.5 days with mortality of around 1–2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.-
dc.languageeng-
dc.publisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtml-
dc.relation.ispartofThe American Journal of Chinese Medicine-
dc.rightsFor preprints : Preprint of an article published in [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL] For postprints : Electronic version of an article published as [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL]-
dc.subjectCOVID-19-
dc.subject2019-nCoV-
dc.subjectChinese Medicine-
dc.subjectIntegrative Medicine-
dc.subjectGuideline-
dc.titleCOVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease-
dc.typeArticle-
dc.identifier.emailChan, KW: chriskwc@hku.hk-
dc.identifier.emailWong, VCW: vcwwong@hku.hk-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1142/S0192415X20500378-
dc.identifier.pmid32164424-
dc.identifier.scopuseid_2-s2.0-85082179878-
dc.identifier.hkuros310462-
dc.identifier.volume48-
dc.identifier.issue3-
dc.identifier.spage737-
dc.identifier.epage762-
dc.identifier.isiWOS:000531883000013-
dc.publisher.placeSingapore-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats